natgillin/translations-raw huggingface dataset:
• Trigger finger (a condition in which your finger or thumb catches in a bent position). 
• sprožilni prst (motnja, pri kateri se kateri od prstov na roki zaskoči v upognjenem položaju)
Do not take Arimidex - if you are allergic (hypersensitive) to anastrozole or any of the other ingredients of Arimidex (see section 6: Further information). 
Ne jemljite zdravila Arimidex - če ste alergični (preobčutljivi) na anastrozol ali katerokoli sestavino zdravila Arimidex (glejte poglavje
Vomiting may be induced if the patient is alert. 
Če je bolnik priseben, se lahko izzove bruhanje.
Genetic toxicology studies with anastrozole show that it is not a mutagen or a clastogen. 
Študije genotoksičnosti anastrozola kažejo, da ni mutagen ali klastogen.
Arimidex does not possess any progestogenic, androgenic, or estrogenic activity. 
Zdravilo Arimidex ne deluje progestagensko, androgensko ali estrogensko.
Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. 
Presnova anastrozola poteka z N-dealkilacijo, hidroksilacijo in glukuronidacijo.
Very common Arthralgia/joint stiffness Arthritis 
Zelo pogosti artralgija/togost sklepov artritis osteoporoza
- if you are taking a medicine that contains tamoxifen or medicines that contain estrogen (see the section called ‘Taking other medicines'). 
- če jemljete kakšno zdravilo, ki vsebuje tamoksifen, ali zdravila, ki vsebujejo estrogene (glejte poglavje
AstraZeneca UK Ltd, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, United Kingdom 
AstraZeneca UK Ltd, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, Velika Britanija
Arimidex should not be used in boys with growth hormone deficiency in addition to growth hormone treatment. 
Zdravila Arimidex se ne sme uporabljati pri dečkih s pomanjkanjem rastnega hormona poleg zdravljenja z rastnim hormonom.
Table 1 Adverse reactions by System Organ Class and frequency Adverse reactions by SOC and frequency Metabolism and nutrition disorders Common 
Preglednica 1 Neželeni učinki po organskih sistemih in pogostnosti Neželeni učinki po organskih sistemih in pogostnosti Presnovne in prehranske motnje
Trial 0046 was an international, multi-centre, open-label exploratory trial of Arimidex in 28 girls (aged 2 to ≤ 10 years) with McCune-Albright Syndrome (MAS). 
Preskušanje 0046 je bilo mednarodno, multicentrično, odprto eksplorativno preskušanje zdravila Arimidex pri 28 deklicah (starih od 2 do ≤ 10 let) z McCune-Albrightovim sindromom (MAS).
The observed fracture rate for Arimidex is similar to the range reported in age-matched postmenopausal populations. 
Z zdravilom Arimidex opaženi delež zlomov je podoben razponu, opisanemu za starostno usklajene populacije po menopavzi.
Distant disease-free survival is defined as the first occurrence of distant recurrence or death (for any reason). 
Preživetje brez oddaljene bolezni je opredeljeno kot prvi pojav oddaljene ponovitve ali smrti (zaradi kateregakoli vzroka).
Since anastrozole reduces estradiol levels, Arimidex must not be used in girls with growth hormone deficiency in addition to growth hormone treatment. 
Anastrozol zmanjša koncentracijo estradiola, zato se zdravila Arimidex ne sme uporabljati pri deklicah s pomanjkanjem rastnega hormona poleg zdravljenja z rastnim hormonom.
While the number of children treated was too limited to draw any reliable conclusions on safety, there was an increased fracture rate and a trend towards reduced bone mineral density in the Arimidex arm compared to placebo. 
Število zdravljenih otrok je bilo sicer premajhno za zanesljive sklepe o varnosti, vendar so v kraku z zdravilom Arimidex v primerjavi s placebom opazili večji delež zlomov in trend k manjši mineralni gostoti kosti.
Mood disturbances 
Motnje razpoloženja
No no-effect levels were established for anastrozole in the toxicity studies, but those effects that were observed at the low doses (1 mg/kg/day) and mid doses (dog 3 mg/kg/day; rat 5 mg/kg/day) were related to either the pharmacological or enzyme inducing properties of anastrozole and were unaccompanied by significant toxic or degenerative changes. 
Toda učinki, opaženi z majhnimi odmerki (1 mg/kg/dan) in srednjimi odmerki (3 mg/kg/dan pri psih, 5 mg/kg/dan pri podganah) so bili povezani bodisi s farmakološkimi učinki anastrozola ali učinki anastrozola na indukcijo encimov in jih niso spremljale pomembne toksične ali degenerativne spremembe.
Arimidex is used to treat breast cancer in women who have gone through the menopause. 
Zdravilo Arimidex se uporablja za zdravljenje raka dojke pri ženskah, ki so že imele menopavzo.
Arimidex is contraindicated during pregnancy (see section 4.3). 
Zdravilo Arimidex je med nosečnostjo kontraindicirano (glejte poglavje 4.3).
[See Annex I - To be completed nationally] This leaflet was last approved in {MM/YYYY}. 
[Glejte Dodatek I - izpolni država članica] Navodilo je bilo odobreno {MM/LLLL}.
The survival of litters born to rats given anastrozole at 0.02 mg/kg/day and above (from Day 17 of pregnancy to Day 22 post-partum) was compromised. 
Preživetje legel, skotenih podganam, ki so dobivale odmerke anastrozola 0,02 mg/kg/dan in več (od 17. dne brejosti do 22. postpartalnega dneva), je bilo slabše.
An open-label, non-comparative, multi-centre study evaluated 14 male patients (aged 2 to 9 years) with familial male-limited precocious puberty, also known as testotoxicosis, treated with combination of Arimidex and bicalutamide. 
Odprta, neprimerjalna, multicentrična študija je ocenila 14 bolnikov moškega spola (starih od 2 do 9 let) z družinsko, na moške omejeno prezgodnjo puberteto (znano tudi kot testotoksikoza), zdravljenih s kombinacijo zdravila Arimidex in bikalutamida.
No statistically significant change in the rate of increase in bone age on treatment compared to the rate during baseline was observed. 
Opazili niso nobene statistično značilne spremembe v hitrosti povečanja kostne starosti med zdravljenjem v primerjavi z izhodiščno hitrostjo.
However, plasma anastrozole concentrations in the volunteers with hepatic cirrhosis were within the range of concentrations seen in normal subjects in other trials. 
Toda koncentracija anastrozola v plazmi je bila pri prostovoljcih s cirozo jeter znotraj območja koncentracij, zabeleženih pri normalnih preiskovancih v drugih preskušanjih.
The apparent clearance (CL/F) of anastrozole, following oral administration, was not altered in volunteers with severe renal impairment (GFR <30ml/min) in Study 1033IL/0018, consistent with the fact that anastrozole is eliminated primarily by metabolism. 
Navidezni očistek (CL/F) anastrozola po peroralni uporabi pri prostovoljcih s hudo okvaro ledvic (hitrost glomerularne filtracije < 30 ml/min) v študiji 1033IL/0018 ni bil drugačen; to se sklada z dejstvom, da se anastrozol odstrani predvsem s presnovo.
In a fertility study weanling male rats were dosed orally with 50 or 400 mg/l anastrozole via their drinking water for 10 weeks. 
V študiji plodnosti so nedavno odstavljenim podganjim samcem 10 tednov peroralno dajali 50 ali 400 mg/l anastrozola v pitni vodi.
In the phase III/IV study (Study of Anastrozole with the Bisphosphonate Risedronate [SABRE]), 234 postmenopausal women with hormone receptor-positive early breast cancer scheduled for treatment with Arimidex 1 mg/day were stratified to low, moderate and high risk groups according to their existing risk of fragility fracture. 
faze SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) so 234 žensk po menopavzi z zgodnjim rakom dojke in pozitivnimi hormonskimi receptorji, ki so bile predvidene za zdravljenje z zdravilom Arimidex 1 mg/dan, razporedili v skupine z majhnim, zmernim in velikim tveganjem glede na njihovo obstoječe tveganje za zlom zaradi krhkosti.
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Arimidex. 
Če niste prepričani, ali kaj od naštetega velja za vas, se posvetujte z zdravnikom ali s farmacevtom, preden vzamete zdravilo Arimidex.
How to store Arimidex Further information 
Shranjevanje zdravila Arimidex Dodatne informacije
The use of specific treatments, e.g., bisphosphonates, may stop further bone mineral loss caused by Arimidex in postmenopausal women and could be considered (see section 4.8). 
Uporaba specifičnih zdravil, npr. difosfonatov, lahko prepreči nadaljnje zmanjševanje mineralne gostote kosti, ki jo pri ženskah po menopavzi povzroči zdravilo Arimidex, zato pride v poštev (glejte poglavje 4.8).
Exposure to anastrozole is not increased in subjects with severe renal impairment (GRF<30ml/min, see section 5.2); in patients with severe renal impairment, administration of Arimidex should be performed with caution (see section 4.2). 
Izpostavljenost anastrozolu se pri osebah s hudo okvaro ledvic ne poveča (GRF<30ml/min, glejte poglavje 5.2); pri bolnicah s hudo okvaro ledvic je treba zdravilo Arimidex uporabljati previdno (glejte poglavje 4.2).
• Bone loss (osteoporosis). 
• redčenje kosti (osteoporoza)
There are no data from the use of Arimidex in pregnant women. 
Podatkov o uporabi zdravila Arimidex pri nosečnicah ni.
• Rare inflammation of your skin that may include red patches or blisters. 
• redko vnetje kože, ki lahko obsega rdeče lise ali mehurje
Arimidex is not recommended for use in children and adolescents due to insufficient data on safety and efficacy (see sections 4.4 and 5.1). 
Zdravila Arimidex zaradi nezadostnih podatkov o varnosti in učinkovitosti ni priporočljivo uporabljati pri otrocih in mladostnikih (glejte poglavji 4.4 in 5.1).
Advanced breast cancer 
Napredovali rak dojke
Time to distant recurrence is defined as the first occurrence of distant recurrence or death due to breast cancer. 
Čas do oddaljene ponovitve je opredeljen kot prvi pojav oddaljene ponovitve ali smrti zaradi raka dojke.
Arimidex is not likely to affect your ability to drive or use any tools or machines. 
Ni verjetno, da bi zdravilo Arimidex vplivalo na vašo sposobnost za upravljanje vozil ali strojev.
Trial 0001 was an open-label, multiple-dose pharmacokinetic study of Arimidex 1 mg/day in 36 pubertal boys with gynaecomastia of less than 12 months duration. 
Preskušanje 0001 je bilo odprta študija farmakokinetike več odmerkov 1 mg zdravila Arimidex na dan pri 36 pubertetnih dečkih z ginekomastijo, ki je trajala manj kot 12 mesecev.
The 12-month main analysis has shown that patients already at moderate to high risk of fragility fracture showed no decrease in their bone mass density (assessed by lumbar spine bone mineral density using DEXA scanning) when managed by using Arimidex 1 mg/day in combination with risedronate 35 mg once a week. 
Glavna analiza po 12 mesecih je pokazala, da se bolnicam z zmernim do velikim tveganjem za zlome zaradi krhkosti gostota kosti (ocenjena z mineralno gostoto kosti v ledveni hrbtenici s slikanjem DEXA) ni zmanjšala, če so bile zdravljenje z zdravilom Arimidex 1 mg/dan v kombinaciji z risedronatom 35 mg enkrat na teden.
No statistically significant change in the frequency of vaginal bleeding days on treatment was observed. 
Med zdravljenjem niso opazili statistično značilne razlike v pogostnosti dni nožnične krvavitve.
• Inflammation of the liver (hepatitis). 
• vnetje jeter (hepatitis)
Second-line therapy in postmenopausal women with advanced breast cancer Arimidex was studied in two controlled clinical trials (Study 0004 and Study 0005) in postmenopausal women with advanced breast cancer who had disease progression following tamoxifen therapy for either advanced or early breast cancer. 
Zdravljenje druge linije pri ženskah z napredovalim rakom dojke Zdravilo Arimidex so raziskali v dveh kontroliranih kliničnih preskušanjih (študija 0004 in študija 0005) pri ženskah po menopavzi z napredovalim rakom dojke, ki jim je bolezen po zdravljenju s tamoksifenom (bodisi zaradi napredovalega ali zgodnjega raka dojke) napredovala.
The primary efficacy parameter was the analysis of lumbar spine bone mass density using DEXA scanning. 
Primarni parameter učinkovitosti je bila analiza gostote kosti v ledveni hrbtenici s slikanjem DEXA.
AstraZeneca UK Ltd Silk Road Business Park Macclesfield Cheshire SK10 2NA United Kingdom 
AstraZeneca UK Ltd Silk Road Business Park Macclesfield Cheshire SK10 2NA Velika Britanija
Keep taking Arimidex for as long as your doctor tells you to. 
Zdravilo Arimidex jemljite toliko časa, kot vam naroči zdravnik.
* Events of Carpal Tunnel Syndrome have been reported in patients receiving Arimidex treatment in clinical trials in greater numbers than those receiving treatment with tamoxifen. 
* Med osebami, ki so v kliničnih preskušanjih prejemale zdravilo Arimidex, so bili primeri sindroma karpalnega kanala opisani v večjem številu kot med osebami, zdravljenimi s tamoksifenom.
In a large phase III study conducted in 9,366 postmenopausal women with operable breast cancer treated for 5 years (see below), Arimidex was shown to be statistically superior to tamoxifen in disease-free survival. 
Velika študija III. faze 9.366 žensk po menopavzi, ki so imele operabilnega raka dojke in so bile zdravljene pet let (glejte spodaj), je pokazala, da je bilo zdravilo Arimidex glede preživetja brez bolezni statistično boljše od tamoksifena.
Somnolence Carpal Tunnel Syndrome* 
Pogosti zaspanost sindrom karpalnega kanala*
Oral administration of anastrozole to female rats produced a high incidence of infertility at 1 mg/kg/day and increased pre-implantation loss at 0.02 mg/kg/day. 
Peroralna uporaba anastrozola pri podganjih samicah je povzročila veliko incidenco neplodnosti pri odmerku 1 mg/kg/dan in večje predimplantacijske izgube pri 0,02 mg/kg/dan.
Disease-free survival includes all recurrence events and is defined as the first occurrence of loco-regional recurrence, contralateral new breast cancer, distant recurrence or death (for any reason). 
Preživetje brez bolezni vključuje vse ponovitvene dogodke in je opredeljeno kot prvi pojav lokoregionalne ponovitve, novega raka dojke na nasprotni dojki, oddaljene ponovitve ali smrti (zaradi kateregakoli vzroka).
If you are not sure, talk to your doctor or pharmacist before taking Arimidex. 
Če ste negotovi, se posvetujte z zdravnikom ali s farmacevtom, preden vzamete zdravilo Arimidex.
A two-year rat oncogenicity study resulted in an increase in incidence of hepatic neoplasms and uterine stromal polyps in females and thyroid adenomas in males at the high dose (25 mg/kg/day) only. 
Dveletna študija onkogenosti na podganah je povzročila povečanje incidence jetrnih novotvorb in materničnih stromalnih polipov pri samicah ter ščitničnih adenomov pri samcih le pri velikih odmerkih (25 mg/kg/dan).
Very common Hot flushes Very common Nausea 
Zelo pogosti valovi vročine
In acute toxicity studies in rodents, the median lethal dose of anastrozole was greater than 100 mg/kg/day by the oral route and greater than 50 mg/kg/day by the intraperitoneal route. 
V študijah akutne toksičnosti na glodalcih je bil mediani smrtni odmerek anastrozola po peroralni uporabi več kot 100 mg/kg/dan in po intraperitonealni uporabi več kot 50 mg/kg/dan.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction for the indicated population. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka za indicirano populacijo.
[See Annex I - To be completed nationally] 
[Glejte Dodatek I - izpolni država članica]
Increases in gamma-GT and bilirubin Hepatitis Very common Rash Common 
Občasni zvišanje gama-GT in bilirubina hepatitis
Anastrozole pharmacokinetics are independent of age in postmenopausal women. 
Farmakokinetika anastrozola pri ženskah po menopavzi ni odvisna od starosti.
A randomised, double-blind, multi-centre study evaluated 52 pubertal boys (aged 11 to 16 years inclusive) with GHD treated for 12 to 36 months with Arimidex 1 mg/day or placebo in combination with growth hormone. 
Randomizirana dvojno slepa multicentrična študija je ocenila 52 pubertetnih dečkov (starih od 11 do vključno 16 let), ki so od 12 do 36 mesecev prejemali 1 mg zdravila Arimidex na dan ali placebo v kombinaciji z rastnim hormonom.
• Inflammation of the joints (arthritis). 
• vnetje sklepov (artritis)
These findings were mirrored in the secondary efficacy variable of change from baseline in total hip BMD at 12 months. 
Ti izsledki so se odrazili na sekundarni spremenljivki učinkovitosti, spremembi celotne mineralne gostote kosti v kolku po 12 mesecih v primerjavi z izhodiščem.
Arimidex has not been investigated in breast cancer patients with moderate or severe hepatic impairment. 
Zdravilo Arimidex ni raziskano pri bolnicah z rakom dojke in zmerno ali hudo okvaro jeter.
Time to recurrence is defined as the first occurrence of loco-regional recurrence, contralateral new breast cancer, distant recurrence or death due to breast cancer. 
Čas do ponovitve je opredeljen kot prvi pojav lokoregionalne ponovitve, novega raka dojke na nasprotni dojki, oddaljene ponovitve ali smrti zaradi raka dojke.
In animal studies toxicity was only seen at high doses. 
V študijah na živalih so toksične učinke opažali samo pri velikih odmerkih.
If this happens to you, ask your doctor or pharmacist for advice. 
Če se vam to zgodi, za nasvet prosite zdravnika ali farmacevta.
If this applies to you, ask your doctor or pharmacist for advice. 
Če to velja za vas, za nasvet prosite zdravnika ali farmacevta.
0.31 to 0.88 
0,31 do 0,88
As Arimidex lowers circulating estrogen levels it may cause a reduction in bone mineral density with a possible consequent increased risk of fracture (see section 4.8). 
Zdravilo Arimidex zmanjša koncentracijo estrogena v obtoku, zato lahko zmanjša mineralno gostoto kosti in tako poveča tveganje zlomov (glejte poglavje 4.8).
Oral administration of anastrozole to pregnant rats and rabbits caused no teratogenic effects at doses up to 1.0 and 0.2 mg/kg/day respectively. 
Peroralno dajanje anastrozola brejim podganam in kunkam ni povzročilo teratogenih učinkov v odmerkih do 1,0 mg/kg/dan (podgane) oz. do 0,2 mg/kg/dan (kunke).
0.63 to 1.46 
0,63 do 1,46
Arimidex should not be used in premenopausal women. 
Zdravila Arimidex se ne sme uporabljati pri ženskah pred menopavzo.
0.19 to 1.13 
0,19 do 1,13
There is no evidence of time or dose-dependency of anastrozole pharmacokinetic parameters. 
Ni znakov, da bi bili farmakokinetični parametri anastrozola odvisni od časa ali odmerka.
Coronary artery disorder 
Bolezen koronarnih arterij
Number of events (frequency) Intention-to-treat population Hormone receptor-positive tumour status 
Število dogodkov (pogostnost) Populacija z-namenomzdravljenja
There were no clinically significant changes in Tanner staging, mean ovarian volume, or mean uterine volume. 
Ugotovili niso nobenih klinično pomembnih razlik v razvrstitvi po Tannerju, povprečnem volumnu jajčnikov in povprečnem volumnu maternice.
0.49 to 0.92 
0,49 do 0,92
Tamoxifen (N=1,282) 
Tamoksifen (n = 1.282)
0.85 to 1.12 
0,85 do 1,12
Arimidex lowers the amount of the hormone called estrogen that is in your body. 
Zdravilo Arimidex zmanjša količino hormona estrogena v telesu.
Arimidex has not been investigated in breast cancer patients with severe renal impairment. 
Zdravilo Arimidex ni raziskano pri bolnicah z rakom dojke in hudo okvaro ledvic.
Tamoxifen (N=3,116) 
Tamoksifen (n = 3.116)
Co-administration of tamoxifen or estrogen-containing therapies with Arimidex should be avoided as this may diminish its pharmacological action (see section 4.5 and 5.1). 
Sočasni uporabi tamoksifena in zdravil, ki vsebujejo estrogene z zdravilom Arimidex se je potrebno izogibati, saj lahko zmanjša njegovo farmakološko delovanje (glejte poglavji 4.5 in 5.1).
0.35 to 0.79 
0,35 do 0,79
Trial 0006 was a randomised, double-blind, multi-centre study of 82 pubertal boys (aged 11-18 years inclusive) with gynaecomastia of greater than 12 months duration treated with Arimidex 1 mg/day or placebo daily for up to 6 months. 
Preskušanje 0006 je bilo randomizirana dvojno slepa multicentrična študija 82 pubertetnih dečkov (starih od 11 do vključno 18 let) z več kot 12 mesecev trajajočo ginekomastijo, ki so do 6 mesecev dobivali 1 mg zdravila Arimidex na dan ali placebo vsak dan.
Co-administration of tamoxifen or estrogen-containing therapies with Arimidex should be avoided as this may diminish its pharmacological action (see section 4.4 and 5.1). 
Sočasni uporabi tamoksifena in zdravil, ki vsebujejo estrogene z zdravilom Arimidex se je potrebno izogibati, saj lahko zmanjša njegovo farmakološko delovanje (glejte poglavji 4.4 in 5.1).
• Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen. 
• Adjuvantno zdravljenje zgodnjega invazivnega raka dojke s pozitivnimi hormonskimi receptorji pri ženskah po menopavzi, ki so 2 do 3 leta dobivale adjuvantni tamoksifen.
Exposure to anastrozole can be increased in subjects with hepatic impairment (see section 5.2); administration of Arimidex in patients with moderate and severe hepatic impairment should be performed with caution (see section 4.2). 
Izpostavljenost anastrozolu je lahko pri osebah z okvaro jeter večja (glejte poglavje 5.2); pri bolnicah z zmerno in hudo okvaro jeter je treba zdravilo Arimidex uporabljati previdno (glejte poglavje 4.2).
In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. 
Pri ženskah po menopavzi je uporaba dnevnega odmerka 1 mg zdravila Arimidex po meritvi z zelo občutljivim preskusom zavrla nastajanje estradiola za več kot
0.80 to 1.07 
0,80 do 1,07
- The other ingredients are: lactose monohydrate, povidone, sodium starch glycollate, magnesium stearate, hypromellose, macrogol 300, titanium dioxide. 
- Pomožne snovi so: laktoza monohidrat, povidon, natrijev karboksimetilškrob, magnezijev stearat,
Tamoxifen (N=2,598) 
Tamoksifen (n = 2.598)
• Pain or stiffness in your joints. 
• bolečine v sklepih ali togost sklepov
0.64 to 0.87 
0,64 do 0,87
Arimidex is contraindicated during breast-feeding (see section 4.3). 
Zdravilo Arimidex je med obdobjem dojenja kontraindicirano (glejte poglavje 4.3).
Plasma anastrozole concentrations observed during longterm efficacy trials in patients with renal impairment were within the range of plasma anastrozole concentrations seen in patients without renal impairment. 
Koncentracija anastrozola v plazmi, zabeležena med dolgotrajnimi preskušanji učinkovitosti pri bolnikih z okvaro ledvic je bila v območju koncentracij anastrozola v plazmi, zabeleženih pri bolnikih brez okvare ledvic.
Plasma anastrozole concentrations observed during long-term efficacy trials in patients with hepatic impairment were within the range of plasma anastrozole concentrations seen in patients without hepatic impairment. 
Koncentracija anastrozola v plazmi, zabeležena med dolgotrajnimi preskušanji učinkovitosti pri bolnikih z okvaro jeter je bila v območju koncentracij anastrozola v plazmi, zabeleženih pri bolnikih brez okvare jeter.
HOW TO TAKE ARIMIDEX 
KAKO JEMATI ZDRAVILO ARIMIDEX
In addition, a decrease in BMD which was not statistically significant was seen in the low risk group treated with Arimidex 1 mg/day alone. 
Poleg tega je bilo v skupini z majhnim tveganjem, ki je dobivala samo zdravilo Arimidex 1 mg/dan, opazno zmanjšanje mineralne gostote kosti, ki pa ni bilo statistično značilno.
Clinical studies with antipyrine and warfarin showed that anastrozole at a 1 mg dose did not significantly inhibit the metabolism of antipyrine and R- and S-warfarin indicating the co-administration of Arimidex with other medicinal products is unlikely to result in clinically significant medicinal product interactions mediated by CYP enzymes. 
Klinične študije z antipirinom in varfarinom so pokazale, da anastrozol v odmerku 1 mg ni bistveno zavrl presnove antipirina ali R- in S-varfarina.
0.70 to 0.90 
0,70 do 0,90